Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | Ribociclib plus everolimus in advanced dedifferentiated liposarcoma

Margaret von Mehren, MD, Fox Chase Cancer Center, Philadelphia, PA, shares the findings of a Phase II trial (NCT03114527) of ribociclib combined with everolimus in patients with dedifferentiated liposarcoma (DDL). In tumor models, ribociclib and everolimus have shown synergistic growth inhibition, leading to the hypothesis that the combination could be of benefit to patients with DDL. Of 19 evaluable patients, 42% met the primary endpoint of non-progression at 16 weeks. A partial response rate of 10% was achieved. The combination was well tolerated, with the most common adverse events being lymphopenia and neutropenia. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Margaret von Mehren, MD has received research funding from Novartis.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.